

Drugs for Alzheimer's Disease

Reprinted with permission from Therapeutics Letter 2005; 56, April - August
(www.ti.ubc.ca/pages/letter56.htm)

References

1. Courtney C, Farrell D, Gray R, et al. for the AD 2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. *Lancet* 2004; 363:2105-2115.
2. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. *Dementia* 1996; 7:293-303.
3. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. *Neurology* 1998; 50:136-145.
4. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. *Arch Intern Med* 1998; 158:1021-1031.
5. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. *Dement Geriatr Cogn Disord* 1999; 10:237-244.
6. Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: a randomized crossover study. *Arch Neurol* 2000; 57:94-99.
7. Mohs RC, Doody RS, Morris JC, et al. for the Donepezil "312" Study Group. A 1-year, placebocontrolled preservation of function survival study of donepezil in AD patients. [erratum appears in *Neurology* 2001; 57:1942]. *Neurology* 2001; 57:481-488.
8. Winblad B, Engedal K, Soininen H, et al. for the Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. *Neurology* 2001; 57:489-495.
9. Feldman H, Gauthier S, Hecker J, et al. for the Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. *Neurology* 2001; 57:613-620.
10. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. *J Am Geriatr Soc* 2001; 49:1590-1599.
11. Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multi center, double-blind, placebo-controlled study in Japan. E2020 Study Group. *Dement Geriatr Cogn Disord* 2000; 11:299-313.
12. Seltzer B, Zolnouni P, Nunez M, et al. for the Donepezil "402" Study Group. Efficacy of Donepezil in Early-Stage Alzheimer Disease: a randomized placebo-controlled trial. [erratum appears in *Arch Neurol* 2005; 62: 825]. *Arch Neurol* 2004; 61:1852-1856.
13. Agid Y, Dubois B, Anand R, Gharabawi G. Efficacy and tolerability of rivastigmine

(Continued on page 2)

A University of Washington Drug Information Center publication
Distributed monthly by authority of the Pharmacy and Therapeutics Committee
Editor: Nelda A. Murri, Pharm.D. (206) 598-6612 – Asst. Editor: Elizabeth Rudy, D.V.M., R.Ph.
Department of Pharmacy Services / School of Pharmacy

Copyright © 2005 by the University of Washington
Also published on the World Wide Web at <http://uw.pnrx.org/therapyTopics.asp>
No material may be reproduced in whole or in part without written permission from the editor.

Drugs for Alzheimer's Disease (continued)

- in patients with dementia of the Alzheimer type. *Curr Ther Res Clin Exp* 1998; 59:837-845.
14. Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with Exelon(TM) (ENA-713) in Alzheimer's disease: An overview. *J Drug Dev Clin Pract* 1996; 8:109-116.
 15. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. *Int J Geriatr Psychopharmacol* 1998; 1:55-65.
 16. Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon(TM)). *Eur J Neurol* 1999; 6:423-429.
 17. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. *Br Med J* 1999; 318:633-640.
 18. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. *The Cochrane Database of Systematic Reviews* 2000, Issue 4. Art. No.:CD001191.
 19. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. *Br Med J* 2000; 321:1445-1449.
 20. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. *Neurology* 2000; 54:2261-2268.
 21. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. *Neurology* 2000; 54:2269-2276.
 22. Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzheimer's disease: a randomized, controlled trial. *J Neurol Neurosurg Psychiatry* 2001; 71:589-595.
 23. Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. *Int J Geriatr Psychiatry* 2001; 16:852-857.
 24. Lanctot KL, Hermann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors for Alzheimer's disease: a meta-analysis. *CMAJ* 2003; 169:557-564.
 25. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H-P, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. *Br Med J* 2005; 331:321-327.
 26. Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. *Int J Clin Pract* 2002; 56:441-446.
 27. Jones RW, Soininen H, Hager K, et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. *Int J Geriatr Psychiatry* 2004; 19:58-67.
 28. Wilcock G, Howe I, Coles H, et al. for the GAL-GBR-2 Study Group. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. *Drugs Aging* 2003; 20:777-789.
 29. Peterson RC, Thomas RG, Grundman M, et al. for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. *N Engl J Med* 2005; 352:2379-2388.
 30. Johnson & Johnson. Synopsis. GAL-INT-11, GAL-INT-18, and GAL-COG-302 (Interim Analysis). Accessed August 4, 2005 at: <http://www.clinicalstudyresults.org/>

(Continued on page 3)

documents/companystudy_96_1.pdf; http://www.clinicalstudyresults.org/documents/company-study_96_2.pdf; http://www.clinicalstudyresults.org/documents/company-study_96_4.pdf

31. Reisberg B, Doody R, Stoffler A, et al. for the Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med* 2003; 348:1333-41.
32. Forest Laboratories Clinical Trial Registry. Study No. MEM-MD-01. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients with Moderate to Severe Dementia of the Alzheimer's Type (unpublished, accessed July 4, 2005 at <http://www.forestclinicaltrials.com/CTR/CTRController/CTRCompletedListStudies>)
33. Tariot PN, Farlow MR, Grossberg GT, et al. for the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. *JAMA* 2004; 291:317-324.